20. Patton CM, Nicholson MA, Ostroff SM, Ries AA, Wachsmuth IK, Tauxe RV. Common somatic O and heat-labile serotypes among Campylobacter strains from sporadic infections in the United States. J Clin Microbiol. 1993;31:1525–30. 21. Barrett TJ, Patton CM, Morris GK. Differentiation of Campylobacter species using phenotypic characterization. Lab Med. 1988;19:96–102. 22. Murray PR. Manual of clinical microbiology. In: Microbiology. 7th ed. Washington: ASM Press; 1999. p. 1773. 23. Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System Annual Report 2001. Atlanta: Department of Health and Human Services. [cited 2003 Nov]. Available from: http://www.cdc.gov/narms/annual/2001/annual_ 01.htm 24. Linton D, Lawson AJ, Owen RJ, Stanley J. PCR detection, identifica- tion to species level, and fingerprinting of Campylobacter jejuni and Campylobacter coli direct from diarrheic samples. J Clin Microbiol. 1997;35:2568–72. 25. Gonzalez I, Grant KA, Richardson PT, Park SF, Collins MD. Specific identification of the enteropathogens Campylobacter jejuni and Campylobacter coli by using a PCR test based on the ceuE gene encoding a putative virulence determinant. J Clin Microbiol. 1997;35:759–63. 26. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing: eighth information- al supplement. Wayne (PA): The Committee; 1998. 27. Hunt JM. Campylobacter. In: Food and Drug Administration bacteri- ological analytical manual. 7th ed. Arlington (VA): AOAC International; 1992. p. 77–91. 28. Lastovica A, Skirrow M. Clinical significance of Campylobacter and related species other than Campylobacter jejuni and C. coli. In: Blaser M, editor. Campylobacter. Washington: American Society for Microbiology; 2000. p. 89–120. 29. Nachamkin I, Ung H, Li M. Increasing fluoroquinolone resistance in Campylobacter jejuni, Pennsylvania, USA, 1982–2001. Emerg Infect Dis. 2002;8:1501–3. 30. Nachamkin I. Antimicrobial susceptibility of Campylobacter jejuni and Campylobacter coli to ciprofloxacin, erythromycin and tetracy- cline from 1982 to 1992. Med Microbiol Lett. 1994;3:300–5. 31. Kiehlbauch J, Simon M, Makowski J. Use of filtration to isolate Campylobacter and related organisms from stools. In: Newell DG, editor. Campylobacters, Helicobacters, and related organisms. New York: Plenum Press; 1996. p. 47–9. 32. McCaig LF, Besser RE, Hughes JM. Antimicrobial drug prescription in ambulatory care settings, United States, 1992–2000. Emerg Infect Dis. 2003;9:432–7. Antimicrobial-resistant Campylobacter 33. Marano NVD, Fiorentino T, Segler S, Carter M, Kassenborg H, Smith K, et al. Fluoroquinolone-resistant Campylobacter causes longer duration of diarrhea than fluoroquinolone-susceptible Campylobacter strains in FoodNet sites. 2nd International Conference on Emerging Infectious Diseases. Atlanta, GA, 2000. 34. Kuschner RA, Trofa AF, Thomas RJ, Hoge CW, Pitarangsi C, Amato S, et al. Use of azithromycin for the treatment of Campylobacter enteritis in travelers to Thailand, an area where ciprofloxacin resist- ance is prevalent. Clin Infect Dis. 1995;21:536–41. 35. Kassenbourg H, Smith K, Vugia D, Rabatsky-Ehr T, Bates M, Dumas N, et al. Fluoroquinolone-resistant infections: eating poultry outside the home and foreign travel are risk factors. Clin Infect Dis. 2004.38 (Supp13):5279–84. 36. Zhao C, Ge B, De Villena J, Sudler R, Yeh E, Zhao S, et al. Prevalence of Campylobacter spp., Escherichia coli, and Salmonella serovars in retail chicken, turkey, pork, and beef from the greater Washington, D.C. area. Appl Environ Microbiol. 2001;67:5431–6. 37. Ge B, White DG, McDermott PF, Girard W, Zhao S, Hubert S, et al. Antimicrobial-resistant Campylobacter species from retail raw meats. Appl Environ Microbiol. 2003;69:3005–7. 38. Animal Health Institute. Antimicrobial volume survey. [cited 2002 Dec 12]. Available from: www.ahi.org 39. McDermott PF, Bodeis SM, English LL, White DG, Walker RD, Zhao S, et al. Ciprofloxacin resistance in Campylobacter jejuni evolves rapidly in chickens treated with fluoroquinolones. J Infect Dis. 2002;185:837–40. 40. Endtz HP, Ruijs GJ, van Klingeren B, Jansen WH, van der Reyden T, Mouton RP. Quinolone resistance in Campylobacter isolated from man and poultry following the introduction of fluoroquinolones in veterinary medicine. J Antimicrob Chemother. 1991;27:199–208. 41. Bager F, Emborg H, Heuer O. DANMAP 2001—Use of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. Vol. 2002. Copenhagen: Statens Serum Institut; 2001. 42. U.S. Food and Drug Administration. The human health impact of flu- oroquinolone-resistant Campylobacter attributed to the consumption of chicken. [cited 2002 15 Jun]. Available from: http://www.fda.gov/cvm/antimicrobial/revisedRA.pdf 43. FDA withdraws approval of two poultry drugs. FDA Consum 2001;35:5. 44. Baker CN. The E-test and Campylobacter jejuni. Diagn Microbiol Infect Dis. 1992;15:469–72 Address for correspondence: Amita Gupta, Johns Hopkins University, Division of Infectious Diseases, 1830 East Monument Street, Room 450E, Baltimore, MD 21287, USA; fax: 410-614-8488; email: agupta25@jhmi.edu Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 6, June 2004 1109